Melanoma Trial, Recruiting NCT05797415 Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT05797415
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Porocarcinoma, Merkel cell carcinoma, or Sebaceous carcinoma (specific rare skin cancers)
  • You have a type of skin melanoma (from sweat or oil glands) that is relatively thick, has grown to a certain depth, and shows signs of active cell division (confirm with trial site for exact measurements)
  • You have melanoma of the conjunctiva (the surface of the eye), whether it is a new diagnosis or has come back, including cases linked to a pre-cancerous eye condition called primary acquired melanosis with atypia
  • You have squamous cell cancer of the eye's glands or ducts that is at an advanced stage (Stage 3 or higher), has come back after treatment, or has spread along nearby nerves
  • You have squamous cell cancer of the surface of the eye that is at Stage 3 or higher and/or has appeared in more than one area
  • You are willing and able to sign a consent form to take part in the study
  • There is no sign of cancer spread to nearby lymph nodes at the time of diagnosis (confirm with trial site)

Who may not be able to join:

  • You are under 18 years of age
  • Your cancer has already spread to other parts of the body (metastatic disease) when first diagnosed
  • You do not meet the inclusion criteria listed above
  • You are unable or unwilling to provide signed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0630154528

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2023
Est. completion
1 March 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Efficacy of lymphoscintigraphic examination and SLN biopsy; Efficacy of lymphoscintigraphic examination and SLN biopsy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov